HSK46575 for metastatic castration‑resistant prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open‑label Phase I study with a dose‑escalation (Phase Ia) using a 3+3 design and a dose‑expansion phase (Phase Ib) to characterize safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally given HSK46575. Phase Ia includes escalation and extension cohorts with about 30 subjects planned, and Phase Ib plans expansion cohorts with no fewer than 60 subjects per cohort. The trial enrolls men with histologically confirmed metastatic castration‑resistant prostate cancer who have castrate testosterone levels and prior progression on novel endocrine therapy and usually taxane chemotherapy. Key outcomes are dose‑limiting toxicities, recommended phase II dose, PK/PD profiles, and preliminary signals of clinical activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male, aged ≥18 years;
2. ECOG (Eastern Cooperative Oncology Group) 0-1, expected survival of ≥ 3 months;
3. Histology or cytology confirmed adenocarcinoma of the prostate;
4. Radiological evidence of metastatic bone or soft tissue lesions;
5. Ongoing medical castration or previous surgical castration;
6. Testosterone at castration level during screening;
7. Prior to screening, subjects with evidence of disease progression while receiving ADT (androgen deprivation therapy);
8. Had progressed on at least one novel endocrine therapy, and had progressed on at least one taxane-based chemotherapy (or those who are intolerant or refuse chemotherapy);
9. The functional level of organs must meet the requirements.

Exclusion Criteria:

1. Subjects with known hypersensitivity to the active ingredient or excipients of HSK46575 Tablets;
2. Subjects who have received any antitumor therapy within 4 weeks (or 5 half-lives, whichever is shorter) prior to the first dose; or treatment with nitrosoureas, bicalutamide, or nilutamide within 6 weeks (or 5 half-lives, whichever is shorter) prior to the first dose;
3. Subjects whose toxicity from prior anticancer therapy remains \> Grade 1 before the first dose;
4. Subjects who have used strong or moderate CYP3A4 inhibitors or inducers, CYP2C9 sensitive substrates, and OCT2 or MATE1 substrates within 14 days or 5 half-lives prior to the first dose of the investigational drug, whichever is longer;
5. Subjects who have undergone Grade 3-4 surgery;
6. Subjects who plan to receive any other antitumor therapy during the study ;
7. Subjects with active metastases to central nervous system;
8. Subjects with serious bone damage caused by prostate cancer bone metastasis as assessed by the investigators;
9. Within 6 months before the first dose, subjects had concurrent pituitary or adrenal dysfunction;
10. Subjects with uncontrolled hypertension;
11. Subjects with central nervous system disorders such as epilepsy and multiple sclerosis;
12. Subjects with active cardiac disease within 6 months prior to the first dose, or a history of arterial or venous thromboembolism;
13. Subjects with a QTc interval prolongation to \>470 ms during the screening period calculated by the Fridericia formula；
14. Subjects with a history of other malignancies;
15. Subjects with a history of immunodeficiency;
16. Subjects with active HBV, HCV, or syphilis infection;
17. Subjects who have participated in other clinical studies within 4 weeks before the first dose;
18. Other conditions.

Where it's running

• West China Hospital of Sichuan University
  Chengdu, Sichuan, China Recruiting

Study contacts

• Study coordinator: Yunfen Li
• Email: liyunfen@haisco.com
• Phone: 18108214952

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Hormone/Drug HSK31858: does it affect the QT interval in healthy adults

  This study tests whether HSK31858 changes the QT/QTc interval in healthy Chinese adults aged 18–45.

  Recruiting Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Jinan, Shandong · NCT07915024

• How HSK31858 behaves in people with different kidney function

  This study tests how the drug HSK31858 moves through and affects people with mild, moderate, or severe kidney impairment compared to those with normal kidney function, in adults with non-cystic fibrosis bronchiectasis.

  Recruiting Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Zhenzhou, Henan · NCT07915011

• See if HSK31858 behaves safely in people with different levels of liver function

  This study tests how HSK31858 behaves in the body and whether it is safe in adults with normal liver function or with mild to severe liver impairment.

  Recruiting Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Zhenzhou, Henan · NCT07913009

• HSK42360-Na tablets with cetuximab in BRAF V600-mutant metastatic colorectal cancer

  This Phase 1/2 study tests whether HSK42360-Na tablets with cetuximab, with or without standard chemotherapy, are safe and may help people whose colorectal cancer has a BRAF V600 mutation that has spread.

  Recruiting Phase 1/2 Haisco Pharmaceutical Group Co., Ltd. · Beijing · NCT07790510

• Test of HSK46256, a PARP1 inhibitor, in adults with advanced solid tumors

  This early-phase study tests whether the drug HSK46256 is safe and tolerable and how it behaves in the body for adults with advanced solid tumors who have exhausted standard therapies.

  Recruiting Phase 1 Haisco Pharmaceutical Group Co., Ltd. · Shanghai · NCT07695142

• Long-term safety and effectiveness of HSK39297 tablets in IgA nephropathy patients who completed prior study

  This phase 2 trial tests whether taking HSK39297 once daily for IgA nephropathy is safe over the long term and helps reduce protein in the urine for patients who completed a previous study and meet criteria.

  Recruiting Phase 2 Haisco Pharmaceutical Group Co., Ltd. · Beijing and 1 other locations · NCT07616700

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.